Blueprint Medicines Corporation

NasdaqGS:BPMC Stock Report

Market Cap: US$6.0b

Blueprint Medicines Valuation

Is BPMC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BPMC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$325.52
Fair Value
71.1% undervalued intrinsic discount
19
Number of Analysts

Below Fair Value: BPMC ($93.94) is trading below our estimate of fair value ($325.52)

Significantly Below Fair Value: BPMC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BPMC?

Key metric: As BPMC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BPMC. This is calculated by dividing BPMC's market cap by their current revenue.
What is BPMC's PS Ratio?
PS Ratio11.8x
SalesUS$508.82m
Market CapUS$6.00b

Price to Sales Ratio vs Peers

How does BPMC's PS Ratio compare to its peers?

The above table shows the PS ratio for BPMC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average25.8x
HALO Halozyme Therapeutics
7.8x13.1%US$7.4b
BBIO BridgeBio Pharma
30.3x40.4%US$6.6b
ROIV Roivant Sciences
61.5x57.9%US$7.5b
ALKS Alkermes
3.7x-0.07%US$5.8b
BPMC Blueprint Medicines
11.8x22.4%US$6.0b

Price-To-Sales vs Peers: BPMC is good value based on its Price-To-Sales Ratio (11.8x) compared to the peer average (25.8x).

Price to Sales Ratio vs Industry

How does BPMC's PS Ratio compare vs other companies in the US Biotechs Industry?

134 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.1x-0.06%US$20.10b
INCY Incyte
3.2x4.0%US$13.63b
MRNA Moderna
3.9x19.3%US$12.70b
EXAS Exact Sciences
3.4x9.3%US$9.13b
BPMC 11.8xIndustry Avg. 11.0xNo. of Companies134PS01632486480+
134 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BPMC is expensive based on its Price-To-Sales Ratio (11.8x) compared to the US Biotechs industry average (11x).

Price to Sales Ratio vs Fair Ratio

What is BPMC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BPMC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.8x
Fair PS Ratio10.7x

Price-To-Sales vs Fair Ratio: BPMC is expensive based on its Price-To-Sales Ratio (11.8x) compared to the estimated Fair Price-To-Sales Ratio (10.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BPMC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$93.94
US$126.79
+35.0%
17.1%US$169.00US$83.00n/a19
Feb ’26US$112.53
US$125.89
+11.9%
16.7%US$167.00US$81.00n/a19
Jan ’26US$87.22
US$125.58
+44.0%
17.7%US$167.00US$81.00n/a19
Dec ’25US$96.38
US$125.58
+30.3%
17.7%US$167.00US$81.00n/a19
Nov ’25US$90.70
US$125.28
+38.1%
18.2%US$167.00US$81.00n/a18
Oct ’25US$90.00
US$127.35
+41.5%
16.7%US$167.00US$77.00n/a17
Sep ’25US$95.54
US$127.35
+33.3%
16.7%US$167.00US$77.00n/a17
Aug ’25US$100.29
US$124.24
+23.9%
16.7%US$167.00US$76.00n/a17
Jul ’25US$109.18
US$119.41
+9.4%
19.3%US$168.00US$75.00n/a17
Jun ’25US$105.56
US$119.41
+13.1%
19.3%US$168.00US$75.00n/a17
May ’25US$94.86
US$98.06
+3.4%
21.6%US$130.00US$50.00n/a17
Apr ’25US$96.42
US$97.38
+1.0%
21.6%US$125.00US$50.00n/a16
Mar ’25US$95.12
US$97.18
+2.2%
21.0%US$125.00US$50.00n/a17
Feb ’25US$79.88
US$90.12
+12.8%
21.9%US$115.00US$50.00US$112.5317
Jan ’25US$92.24
US$85.41
-7.4%
23.5%US$115.00US$50.00US$87.2217
Dec ’24US$72.05
US$79.50
+10.3%
21.4%US$114.00US$50.00US$96.3818
Nov ’24US$59.90
US$79.00
+31.9%
20.7%US$114.00US$50.00US$90.7018
Oct ’24US$50.22
US$74.59
+48.5%
26.1%US$114.00US$40.00US$90.0017
Sep ’24US$50.64
US$74.00
+46.1%
25.9%US$114.00US$40.00US$95.5417
Aug ’24US$64.14
US$74.41
+16.0%
26.4%US$114.00US$42.00US$100.2917
Jul ’24US$63.20
US$73.12
+15.7%
27.7%US$114.00US$42.00US$109.1817
Jun ’24US$56.79
US$73.06
+28.6%
27.7%US$114.00US$46.00US$105.5617
May ’24US$51.50
US$68.71
+33.4%
32.9%US$114.00US$38.00US$94.8617
Apr ’24US$44.99
US$68.88
+53.1%
33.0%US$114.00US$38.00US$96.4217
Mar ’24US$43.15
US$68.65
+59.1%
32.9%US$114.00US$38.00US$95.1217
Feb ’24US$46.05
US$75.35
+63.6%
33.6%US$115.00US$39.00US$79.8817
Analyst Price Target
Consensus Narrative from 19 Analysts
US$126.79
Fair Value
25.9% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 02:55
End of Day Share Price 2025/02/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Blueprint Medicines Corporation is covered by 30 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Ishan MajumdarBaptista Research
Peter LawsonBarclays